NUCLEOME THERAPEUTICS LIMITED - Profile & Financials

Accounts Submitted 8 Apr 2025

Confirmation Statement Submitted 2 Sept 2025

Net assets £26.80M £3.77M 2024 year on year

Total assets £27.63M £3.29M 2024 year on year

Total Liabilities £831.83K £480.91K 2024 year on year

Charges None No charges registered

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Contact

Update Details

Registered Address

Nucleome Therapeutics Limited, Inventa Botley Road Oxford OX2 0HA United Kingdom

Office (Oxford)

The Schroedinger Building, The Oxford Science Park, Heatley Rd, Littlemore, Oxford OX4 4GE

Telephone

0186 534 6060

careers@nucleome.com

Website

nucleome.com

Credit Report

Discover NUCLEOME THERAPEUTICS LIMITED's Credit Score, limit, and payment likelihood.

Mutual Companies

See All Mutual Companies

Financials

Period 1 Jan → 31 Dec 2024

Type Total Exemption Full

Next accounts 31 December 2025

Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2020–2024)

Cash in Bank

£19.87M

Increased by £7.57M (+62%)

Net Assets

£26.80M

Increased by £3.77M (+16%)

Total Liabilities

£831.83k

Decreased by £480.91k (-37%)

Turnover

£25.21k

Decreased by £130.85k (-84%)

Employees

Decreased by 10 (-23%)

Debt Ratio

Decreased by 2 (-40%)

Financial History

Revenue, profit, EBITDA and key financial figures

	2024 Dec Year End	2024 Dec Year End
P&L
Revenue	£142.3M	£128.7M
Gross Profit	£48.2M	£43.1M
Operating Profit	£22.4M	£19.8M
Net Profit	£18.1M	£15.9M
EBITDA	£31.5M	£28.2M
Assets
Cash	£24.7M	£21.3M
Total Assets	£89.4M	£82.1M
Liabilities
Total Liabilities	£45.2M	£41.8M
Key Metrics
Employees	1,247	1,156

Latest Revenue

£142.3M

Latest EBITDA

£31.5M

Cash Position

£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share allotments and capital structure

21 Allotments 31,375,921 Shares £23.96m Total

Date From	Share Class	Shares Allotted	Amount Raised	Price/Share
15 Sept 2025	ORDINARY	8,206	£0.082	£0
10 Sept 2025	ORDINARY	443,331	£4.433	£0
8 Jul 2025	ORDINARY	11,990	£0.12	£0
7 Apr 2025	ORDINARY	23,883	£0.239	£0
7 Apr 2025	ORDINARY	23,883	£0.239	£0

Officers

9 active 3 resigned

Show resigned officers

						Status
Bauke Anninga	Director	Dutch	Netherlands	39	21 Oct 2022	Active
Emma Johnson	Director	British	United Kingdom	29	2 Mar 2023	Active
Fiona Caroline Maclaughlin	Director	British	England	54	21 Oct 2022	Active
James Raymond Hughes	Director	British,irish	United Kingdom	57	17 Jul 2019	Active
John Davis	Director	American	United States	63	15 Feb 2024	Active
Jonathan Paul Hepple	Director	British	United Kingdom	54	30 Nov 2020	Active
Mark Bodmer	Director	British	United Kingdom	68	24 Jul 2024	Active
Rana Abdul Raouf Al-hallaq	Director	American	United States	50	21 Oct 2022	Active

Shareholders

Shareholders (30)


Phil Boyd	0.2%	218,565	Deferred	2 Sept 2025
Ramon Casero Canas	0.0%	15,907	Ordinary	2 Sept 2025
Roberta Baronio	0.0%	3,762	Ordinary	2 Sept 2025

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Oxford Science Enterprises Plc

United Kingdom

Active

Notified 2 Aug 2019

Nature of Control

Voting Rights 25 To 50 Percent

James Raymond Hughes

Ceased 29 Jul 2019

Ceased

See All Controllers

Group Structure

OXFORD SCIENCE ENTERPRISES PLC united kingdom

NUCLEOME THERAPEUTICS LIMITED Current Company

Charges

No charges registered

Documents

Company Filings

Date	Category	Description	Document
17 Sept 2025	Capital	Allotment of shares (GBP 1,018.68052) on 2025-09-15	View(4 pages)
12 Sept 2025	Capital	Allotment of shares (GBP 1,018.59846) on 2025-09-10	View(4 pages)
2 Sept 2025	Confirmation Statement	Confirmation statement made on 2025-08-16 with updates	View(8 pages)
10 Jul 2025	Capital	Allotment of shares (GBP 1,014.16515) on 2025-07-08	View(4 pages)
6 Jun 2025	Officers	Appointment of Dr Russell George Greig as director	View(3 pages)